– Pure-Vu® System available on pilot basis with leading U.S.
hospitals conducting post-approval clinical trials and market
development programs in advance of 2019 commercial launch

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--
Motus
GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a
medical technology company dedicated to improving clinical outcomes and
enhancing the cost-efficiency of colonoscopy, announced today the first
successful clinical cases were completed in late October with the
Company’s Pure-Vu® Slim Sleeve, a compatible extension to the Pure-Vu®
System for slim colonoscopes. The Company recently announced that the
Pure-Vu® Slim Sleeve had received special 510(k) clearance from the U.S.
Food and Drug Administration (FDA).

Pure-Vu® Slim Sleeve has the same cleansing performance as the standard
Pure-Vu® Sleeve and both versions work with the same Pure-Vu®
workstation control system. The Pure-Vu® Slim Sleeve has been designed
to be compatible with smaller diameter and more flexible slim
colonoscopes with additional enhancements to the Company’s low friction
lubricious coating technology to aid in navigation through the colon.
The Pure-Vu® Slim Sleeve enables access to the full colonoscopy market
where Motus GI estimates, through consultation with colonoscope
manufacturing companies, approximately 30% of procedures are performed
with a slim colonoscope. In total, 15 colonoscopies were completed in
the last few weeks of October at select hospitals using Pure-Vu® Slim
Sleeve.

“Based on my initial experience, I am impressed with the usability and
effectiveness of the Pure-Vu® Slim Sleeve, especially the fact that the
cleaning performance of the Pure-Vu® Slim Sleeve is just as powerful as
the Pure-Vu® Sleeve. Being able to utilize the Pure-Vu® System in
critically ill inpatients to improve and expedite care is where I have
found the slim colonoscope most advantageous,” noted Melissa Latorre,
M.D. from NYU Langone Health in NY.

“We are excited by the early clinical use feedback on the Pure-Vu® Slim
Sleeve, which was designed with the same stringent standards used for
the Pure-Vu® System. The Pure-Vu® System has demonstrated the ability to
rapidly cleanse the colon and overcome the high rates of insufficient
bowel prep in the inpatient setting. With the addition of the Pure-Vu®
Slim Sleeve, we are able to target the full range of inpatient
procedures,” commented Tim
Moran, Chief Executive Officer of Motus GI. “Our focus remains on
the successful execution of our ongoing REDUCE clinical trial, launch of
our EXPEDITE study, and our expanding market development programs with
leading U.S. hospitals that are utilizing the Pure-Vu® System on a pilot
basis. We will continue to drive the completion of these key activities
and milestones in advance of our commercial launch in 2019.”

The Pure-Vu® System generates a proprietary pulsed vortex™ mixture of
water and air to safely remove debris from the colon mucosa while
simultaneously evacuating the bowel contents, clearing the way for the
endoscopist to perform a quality examination even when the patient does
not or is not able to complete a successful prep on his or her own. The
Pure-Vu® System consists of a disposable sleeve, now available in
standard and slim versions, which fits over a colonoscope without
interfering with the working channel, as well a workstation controller.

Motus GI’s clinical trials, such as the ongoing REDUCE study and its
upcoming EXPEDITE study, are designed to evaluate the Pure-Vu® System’s
ability to rapidly cleanse the colon intra-procedurally during emergent
colonoscopies done on an inpatient basis in hospitals, and to assess the
Pure-Vu® System’s ability to reduce the time to successful diagnosis and
eliminate delays, costs and complications associated with conventional
bowel preparation requirements.

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving clinical
outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s
flagship product is the Pure-Vu® System, a U.S. FDA cleared
medical device indicated to help facilitate the cleaning of a poorly
prepared colon during the colonoscopy procedure. The device integrates
with standard and slim colonoscopes to enable safe and rapid cleansing
during the procedure while preserving established procedural workflow
and techniques. The Pure-Vu® System has received CE mark
approval in Europe. The Pure-Vu® System is currently being
introduced on a pilot basis in the U.S. market, and the Company is
planning to initiate a full commercial launch focused on the inpatient
colonoscopy market in the U.S. and select international markets in 2019.
Challenges with bowel preparation for inpatient colonoscopy represent a
significant area of unmet need that directly affects clinical outcomes
and increases the cost of care in a market segment that comprises
approximately 1.5 million annual procedures in the U.S. and
approximately 4 million annual procedures worldwide. Motus GI believes
the Pure-Vu® System may improve outcomes and lower costs for
hospitals by reducing the time to successful colonoscopy, minimizing
delayed and incomplete procedures, and improving the quality of an exam.
In clinical studies to date, the Pure-Vu® System
significantly increased the number of patients with an adequate
cleansing level, according to the Boston Bowel Preparation Scale Score,
a validated assessment instrument.

This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, "expect," "anticipate," "intend," "plan,"
"believe," "estimate," "potential," "predict," "project," "should,"
"would" and similar expressions and the negatives of those terms,
including without limitation, risks inherent in the development and
commercialization of potential products, uncertainty in the timing and
results of clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the Company’s
Form 10-K filed on March 28, 2018, and its other filings with the
Securities and Exchange Commission. Prospective investors are cautioned
not to place undue reliance on such forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.